X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with GSK Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs GSK PHARMA - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD GSK PHARMA BIOCON LTD/
GSK PHARMA
 
P/E (TTM) x 77.5 63.4 122.2% View Chart
P/BV x 7.3 10.2 71.6% View Chart
Dividend Yield % 0.2 1.2 13.7%  

Financials

 BIOCON LTD   GSK PHARMA
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
GSK PHARMA
Mar-17
BIOCON LTD/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1623,838 30.3%   
Low Rs4832,637 18.3%   
Sales per share (Unadj.) Rs194.6354.2 54.9%  
Earnings per share (Unadj.) Rs34.439.8 86.5%  
Cash flow per share (Unadj.) Rs48.342.9 112.6%  
Dividends per share (Unadj.) Rs1.0030.00 3.3%  
Dividend yield (eoy) %0.10.9 13.1%  
Book value per share (Unadj.) Rs241.9236.9 102.1%  
Shares outstanding (eoy) m200.0084.70 236.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.29.1 46.2%   
Avg P/E ratio x23.981.4 29.4%  
P/CF ratio (eoy) x17.075.5 22.6%  
Price / Book Value ratio x3.413.7 24.9%  
Dividend payout %2.975.4 3.9%   
Avg Mkt Cap Rs m164,440274,216 60.0%   
No. of employees `0009.24.7 196.6%   
Total wages/salary Rs m7,4704,830 154.7%   
Avg. sales/employee Rs Th4,213.96,387.0 66.0%   
Avg. wages/employee Rs Th809.01,028.3 78.7%   
Avg. net profit/employee Rs Th745.2717.1 103.9%   
INCOME DATA
Net Sales Rs m38,91130,000 129.7%  
Other income Rs m1,571728 215.7%   
Total revenues Rs m40,48230,728 131.7%   
Gross profit Rs m9,7954,190 233.8%  
Depreciation Rs m2,772263 1,054.0%   
Interest Rs m2600-   
Profit before tax Rs m8,3344,655 179.0%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m1,6161,744 92.7%   
Profit after tax Rs m6,8813,368 204.3%  
Gross profit margin %25.214.0 180.2%  
Effective tax rate %19.437.5 51.8%   
Net profit margin %17.711.2 157.5%  
BALANCE SHEET DATA
Current assets Rs m40,47716,742 241.8%   
Current liabilities Rs m16,7837,202 233.0%   
Net working cap to sales %60.931.8 191.5%  
Current ratio x2.42.3 103.8%  
Inventory Days Days6052 115.0%  
Debtors Days Days8321 398.7%  
Net fixed assets Rs m45,0738,635 522.0%   
Share capital Rs m1,000847 118.1%   
"Free" reserves Rs m47,37719,222 246.5%   
Net worth Rs m48,37720,069 241.1%   
Long term debt Rs m21,08210 210,820.0%   
Total assets Rs m93,94230,038 312.7%  
Interest coverage x33.1NM-  
Debt to equity ratio x0.40 87,455.9%  
Sales to assets ratio x0.41.0 41.5%   
Return on assets %7.611.2 67.8%  
Return on equity %14.216.8 84.8%  
Return on capital %12.625.5 49.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,988528 2,459.8%   
Fx outflow Rs m7,8997,193 109.8%   
Net fx Rs m5,089-6,665 -76.4%   
CASH FLOW
From Operations Rs m6,4002,360 271.2%  
From Investments Rs m-4,9853,008 -165.7%  
From Financial Activity Rs m-1,775-5,108 34.8%  
Net Cashflow Rs m-473260 -181.7%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 50.7 40.6%  
Indian inst/Mut Fund % 8.4 10.2 82.4%  
FIIs % 10.7 23.8 45.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 102,036 107.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare BIOCON LTD With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Losses; Capital Goods Sector Down 1.7%(11:30 am)

Indian share markets are presently trading on a negative note. Sectoral indices are trading in the red with stocks in the capital goods sector and metal sector witnessing maximum selling pressure.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Feb 19, 2018 12:23 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD - AJANTA PHARMA COMPARISON

COMPARE BIOCON LTD WITH

MARKET STATS